The potential of nicotinic enhancement of cognitive remediation training in schizophrenia

Neuropharmacology

Volumn 64, Issue , 2013, Pages 185-190

  Hahn, Britta ^a   Gold, James M ^a   Buchanan, Robert W ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Augmentation; Cognition; Cognitive remediation; Nicotinic; Schizophrenia; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; MODAFINIL; MUSCARINIC AGENT; NEUROLEPTIC AGENT; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; SEROTONIN 3 ANTAGONIST;

ALERTNESS; ATTENTION; COGNITIVE DEFECT; COGNITIVE ENHANCEMENT THERAPY; COGNITIVE REMEDIATION TRAINING; COGNITIVE THERAPY; DRUG EFFECT; DRUG MECHANISM; HUMAN; LEARNING; MEMORY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SMOKING;

ANIMALS; BRAIN; COGNITION DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; NICOTINIC AGONISTS; NOOTROPIC AGENTS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA;

EID: 84866435110     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.05.050     Document Type: Review

References (120)

1. J.B. Acri, D.E. Morse, E.J. Popke, and N.E. Grunberg Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats Psychopharmacology 114 1994 369 374
2. C.E. Adams, and K.E. Stevens Evidence for a role of nicotinic acetylcholine receptors in schizophrenia Front. Biosci. 12 2007 4755 4772
3. R.A. Adcock, C. Dale, M. Fisher, S. Aldebot, A. Genevsky, G.V. Simpson, S. Nagarajan, and S. Vinogradov When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia Schizophr Bull. 35 2009 1132 1141
4. C.G. AhnAllen, P.G. Nestor, M.E. Shenton, R.W. McCarley, and M.A. Niznikiewicz Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia Schizophr Res. 100 2008 261 269
5. S. Akhondzadeh, N. Mohammadi, M. Noroozian, N. Karamghadiri, A. Ghoreishi, A.H. Jamshidi, and S. Forghani Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial Schizophr Res. 107 2009 206 212
6. R.S. Barr, M.A. Culhane, L.E. Jubelt, R.S. Mufti, M.A. Dyer, A.P. Weiss, T. Deckersbach, J.F. Kelly, O. Freudenreich, D.C. Goff, and A.E. Evins The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls Neuropsychopharmacology 33 2008 480 490
7. M. Bell, G. Bryson, T. Greig, C. Corcoran, and B.E. Wexler Neurocognitive enhancement therapy with work therapy - effects on neuropsychological test performance Arch. Gen. Psychiatry 58 2001 763 768
8. M. Bell, J. Fiszdon, T. Greig, B. Wexler, and G. Bryson Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance J. Rehabil. Res. Dev. 44 2007 761 770
9. R.J. Beninger, T.W. Baker, M.M. Florczynski, and T.J. Banasikowski Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients Neurotox. Res. 18 2010 229 243
10. J.J. Buccafusco, S.R. Letchworth, M. Bencherif, and P.M. Lippiello Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance Trends Pharmacol. Sci. 26 2005 352 360
11. S.A. Castner, G.N. Smagin, T.M. Piser, Y. Wang, J.S. Smith, E.P. Christian, L. Mrzljak, and G.V. Williams Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors Biol. Psychiatry 69 2011 12 18
12. S. Chouinard, A.A. Sepehry, and E. Stip Oral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, part I Clin. Neuropharmacol. 30 2007 169 182
13. J.M. Conner, A. Culberson, C. Packowski, A.A. Chiba, and M.H. Tuszynski Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning Neuron 38 2003 819 829
14. G.W. Dalack, D.J. Healy, and J.H. Meador-Woodruff Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings Am. J. Psychiatry 155 1998 1490 1501
15. J.A. Dani, and D. Bertrand Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system Annu. Rev. Pharmacol. Toxicol. 47 2007 699 729
16. L. Depatie, G.A. O'Driscoll, A.L. Holahan, V. Atkinson, J.X. Thavundayil, N.N. Kin, and S. Lal Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study Neuropsychopharmacology 27 2002 1056 1070
17. G. Dunbar, P.H. Boeijinga, A. Demazières, C. Cisterni, R. Kuchibhatla, K. Wesnes, and R. Luthringer Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers Psychopharmacology (Berl) 191 2007 919 929
18. S.M. Eack, D.P. Greenwald, S.S. Hogarty, S.J. Cooley, A.L. DiBarry, D.M. Montrose, and M.S. Keshavan Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial Psychiatr. Serv. 60 2009 1468 1476
19. S.M. Eack, G.E. Hogarty, R.Y. Cho, K.M.R. Prasad, D.P. Greenwald, S.S. Hogarty, and M.S. Keshavan Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia results from a 2-year randomized controlled trial Arch. Gen. Psychiatry 67 2010 674 682
20. D.J. Fisher, T.L. Scott, D.K. Shah, S. Prise, M. Thompson, and V.J. Knott Light up and see: enhancement of the visual mismatch negativity (vMMN) by nicotine Brain Res. 1313 2010 162 171
21. M. Fisher, C. Holland, M.M. Merzenich, and S. Vinogradov Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia Am. J. Psychiatry 166 2009 805 811
22. M. Fisher, C. Holland, K. Subramaniam, and S. Vinogradov Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later Schizophr Bull. 36 2010 869 879
23. J. Foulds, J. Stapleton, J. Swettenham, N. Bell, K. McSorley, and M.A.H. Russell Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers Psychopharmacology 127 1996 31 38
24. R. Freedman, H. Coon, M. MylesWorsley, A. OrrUrtreger, A. Olincy, A. Davis, M. Polymeropoulos, J. Holik, J. Hopkins, M. Hoff, J. Rosenthal, M.C. Waldo, F. Reimherr, P. Wender, J. Yaw, D.A. Young, C.R. Breese, C. Adams, D. Patterson, L.E. Adler, L. Kruglyak, S. Leonard, and W. Byerley Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus Proc. Natl. Acad. Sci. U S A 94 1997 587 592
25. R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, L. Johnson, D. Allensworth, A. Guzman-Bonilla, B. Clement, M.P. Ball, J. Kutnick, V. Pender, L.F. Martin, K.E. Stevens, B.D. Wagner, G.O. Zerbe, F. Soti, and W.R. Kem Initial phase 2 trial of a nicotinic agonist in schizophrenia Am. J. Psychiatry 165 2008 1040 1047
26. M.S. George, C.E. Molnar, E.L. Grenesko, B. Anderson, Q. Mu, K. Johnson, Z. Nahas, M. Knable, P. Fernandes, J. Juncos, X. Huang, D.E. Nichols, and R.B. Mailman A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia Schizophr Res. 93 2007 42 50
27. T.P. George, J.C. Vessicchio, A. Termine, D.M. Sahady, C.A. Head, W.T. Pepper, T.R. Kosten, and B.E. Wexler Effects of smoking abstinence on visuospatial working memory function in schizophrenia Neuropsychopharmacology 26 2002 75 85
28. S.D. Glick, E.M. Sell, S.E. McCallum, and I.M. Maisonneuve Brain regions mediating alpha3bet4 nicotinic antagonist effects of 18-MC on nicotine self-administration European Journal of Pharmacology 669 2011 71 75
29. D.C. Goff, C. Cather, J.D. Gottlieb, A.E. Evins, J. Walsh, L. Raeke, M.W. Otto, D. Schoenfeld, and M.F. Green Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study Schizophr Res. 106 2008 320 327
30. D.C. Goff, J.S. Lamberti, A.C. Leon, M.F. Green, A.L. Miller, J. Patel, T. Manschreck, O. Freudenreich, and S.A. Johnson A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia Neuropsychopharmacology 33 2008 465 472
31. C. Gotti, F. Clementi, A. Fornari, A. Gaimarri, S. Guiducci, I. Manfredi, M. Moretti, P. Pedrazzi, L. Pucci, and M. Zoli Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 78 2009 703 711
32. C. Gotti, S. Guiducci, V. Tedesco, S. Corbioli, L. Zanetti, M. Moretti, A. Zanardi, R. Rimondini, M. Mugnaini, F. Clementi, C. Chiamulera, and M. Zoli Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha 6 beta 2*receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement J. Neurosci. 30 2010 5311 5325
33. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153 1996 321 330
34. M.F. Green, R.S. Kern, and R.K. Heaton Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS Schizophr Res. 72 2004 41 51
35. A.J. Grottick, M. Haman, R. Wyler, and G.A. Higgins Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands Neuropsychopharmacology 28 2003 880 887
36. A.J. Grottick, and G.A. Higgins Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task Behav. Brain Res. 117 2000 197 208
37. B. Hahn, C.G. Sharples, S. Wonnacott, M. Shoaib, and I.P. Stolerman Attentional effects of nicotinic agonists in rats Neuropharmacology 44 2003 1054 1067
38. B. Hahn, M. Shoaib, and I.P. Stolerman Effects of dopamine receptor antagonists on nicotine-induced attentional enhancement Behav. Pharmacol. 13 2002 621 632
39. B. Hahn, M. Shoaib, and I.P. Stolerman Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands Psychopharmacology (Berl) 162 2002 129 137
40. B. Hahn, M. Shoaib, and I.P. Stolerman Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement Psychopharmacology 217 2011 75 82
41. B. Hahn, and I.P. Stolerman Nicotine-induced attentional enhancement in rats: effects of chronic exposure to nicotine Neuropsychopharmacology 27 2002 712 722
42. B. Hahn, and I.P. Stolerman Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists Psychopharmacology (Berl) 177 2005 438 447
43. S. Hamid, G.S. Dawe, J.A. Gray, and J.D. Stephenson Nicotine induces long-lasting potentiation in the dentate gyrus of nicotine-primed rats Neurosci. Res. 29 1997 81 85
44. M.E. Hasselmo The role of acetylcholine in learning and memory Curr. Opin. Neurobiol. 16 2006 710 715
45. K.M. Haut, K.O. Lim, and A. MacDonald III Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity Neuropsychopharmacology 35 2010 1850 1859
46. S.J. Heishman, and J.E. Henningfield Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers Psychopharmacology (Berl) 152 2000 321 333
47. S.J. Heishman, B.A. Kleykamp, and E.G. Singleton Meta-analysis of the acute effects of nicotine and smoking on human performance Psychopharmacology (Berl) 210 2010 453 469
48. S.J. Heishman, R.C. Taylor, and J.E. Henningfield Nicotine and smoking: a review of effects on human performance Exp. Clin. Psychopharmacol. 2 1994 345 395
49. J.E. Henningfield, and R.M. Keenan Nicotine delivery kinetics and abuse liability J. Consulting Clin. Psychol. 61 1993 743 750
50. G.E. Hogarty, S. Flesher, R. Ulrich, M. Carter, D. Greenwald, M. Pogue-Geile, M. Kechavan, S. Cooley, A.L. DiBarry, A. Garrett, H. Parepally, and R. Zoretich Cognitive enhancement therapy for schizophrenia - effects of a 2-year randomized trial on cognition and behavior Arch. Gen. Psychiatry 61 2004 866 876
51. L.E. Hong, G.K. Thaker, R.P. McMahon, A. Summerfelt, J. Rachbeisel, R.L. Fuller, I. Wonodi, R.W. Buchanan, C. Myers, S.J. Heishman, J. Yang, and A. Nye Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder Arch. Gen. Psychiatry 2011
52. E.J. Houtsmuller, J.E. Henningfield, and M.L. Stitzer Subjective effects of the nicotine lozenge: assessment of abuse liability Psychopharmacology (Berl) 167 2003 20 27
53. J.R. Hughes Effects of abstinence from tobacco: valid symptoms and time course Nicotine Tob. Res. 9 2007 315 327
54. D.C. Javitt Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia Audiol. Neurootol. 5 2000 207 215
55. D.C. Javitt, E. Liederman, A. Cienfuegos, and A.M. Shelley Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia Schizophr Bull. 25 1999 763 775
56. C.E. Johanson, and M.W. Fischman The pharmacology of cocaine related to its abuse Pharmacol. Rev. 41 1989 3 52
57. L.E. Jubelt, R.S. Barr, D.C. Goff, T. Logvinenko, A.P. Weiss, and A.E. Evins Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia Psychopharmacology (Berl) 199 2008 89 98
58. Y. Kawakubo, K. Kasai, N. Kudo, M.A. Rogers, K. Nakagome, K. Itoh, and N. Kato Phonetic mismatch negativity predicts verbal memory deficits in schizophrenia Neuroreport 17 2006 1043 1046
59. T.A. Keller, and M.A. Just Altering cortical connectivity: remediation-induced changes in the white matter of poor readers Neuron 64 2009 624 631
60. J.W. Kenney, and T.J. Gould Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine Mol. Neurobiol. 38 2008 101 121
61. V.J. Knott, D.J. Fisher, and A.M. Millar Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors Neuroscience 170 2010 816 826
62. H.S. Koelega Stimulant drugs and vigilance performance: a review Psychopharmacology (Berl) 111 1993 1 16
63. B.T. Kugler, and D.J. Caudrey Phoneme discrimination in schizophrenia Br. J. Psychiatry 142 1983 53 59
64. A.L. Larrison-Faucher, A.A. Matorin, and A.B. Sereno Nicotine reduces antisaccade errors in task impaired schizophrenic subjects Prog. Neuropsychopharmacol. Biol. Psychiatry 28 2004 505 516
65. A.F. Lehman Improving treatment for persons with schizophrenia Psychiatr. Quart. 70 1999 259 272
66. J. LeHouezec, R. Halliday, N.L. Benowitz, E. Callaway, H. Naylor, and K. Herzig A low dose of subcutaneous nicotine improves information processing in non-smokers Psychopharmacology 114 1994 628 634
67. S.C. Leiser, M.R. Bowlby, T.A. Comery, and J. Dunlop A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits Pharmacol. Ther. 122 2009 302 311
68. D.I. Leitman, P. Laukka, P.N. Juslin, E. Saccente, P. Butler, and D.C. Javitt Getting the cue: sensory contributions to auditory emotion recognition impairments in schizophrenia Schizophr Bull. 36 2010 545 556
69. S. Leonard, J. Gault, J. Hopkins, J. Logel, R. Vianzon, M. Short, C. Drebing, R. Berger, D. Venn, P. Sirota, G. Zerbe, A. Olincy, R.G. Ross, L.E. Adler, and R. Freedman Association of promoter variants in the alpha 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia Arch. Gen. Psychiatry 59 2002 1085 1096
70. E.D. Levin Nicotinic receptor subtypes and cognitive function J. Neurobiol. 53 2002 633 640
71. E.D. Levin, C.K. Conners, D. Silva, S.C. Hinton, W.H. Meck, J. March, and J.E. Rose Transdermal nicotine effects on attention Psychopharmacology 140 1998 135 141
72. E.D. Levin, F.J. McClernon, and A.H. Rezvani Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization Psychopharmacology 184 2006 523 539
73. J.A. Lieberman, K. Papadakis, J. Csernansky, R. Litman, J. Volavka, X.D. Jia, and A. Gage A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology 34 2009 1322 1329
74. E.A. Maguire, D.G. Gadian, I.S. Johnsrude, C.D. Good, J. Ashburner, R.S. Frackowiak, and C.D. Frith Navigation-related structural change in the hippocampi of taxi drivers Proc. Natl. Acad. Sci. U S A 97 2000 4398 4403
75. H.D. Mansvelder, J.R. Keath, and D.S. McGehee Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas Neuron 33 2002 905 919
76. L.F. Martin, and R. Freedman Schizophrenia and the alpha7 nicotinic acetylcholine receptor Int. Rev. Neurobiol. 78 2007 225 246
77. L.F. Martin, W.R. Kem, and R. Freedman Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia Psychopharmacology 174 2004 54 64
78. R. Mass, K. Wolf, M. Wagner, and C. Haasen Differential sustained attention/vigilance changes over time in schizophrenics and controls during a degraded stimulus Continuous Performance Test Eur. Arch. Psychiatry Clin. Neurosci. 250 2000 24 30
79. S. Matsuyama, A. Matsumoto, T. Enomoto, and T. Nishizaki Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus Eur. J. Neurosci. 12 2000 3741 3747
80. S.R. McGurk, E.W. Twamley, D.I. Sitzer, G.J. McHugo, and K.T. Mueser A meta-analysis of cognitive remediation in schizophrenia Am. J. Psychiatry 164 2007 1791 1802
81. A. Medalia, and J. Choi Cognitive remediation in schizophrenia Neuropsychol. Rev. 19 2009 353 364
82. A. Mike, N.G. Castro, and E.X. Albuquerque Choline and acetylcholine have similar kinetic properties of activation and desensitization on the alpha7 nicotinic receptors in rat hippocampal neurons Brain Res. 882 2000 155 168
83. S.K. Min, I.W. Moon, R.W. Ko, and H.S. Shin Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers Psychopharmacology (Berl) 159 2001 83 88
84. C.S. Myers, O. Robles, A.N. Kakoyannis, J.D. Sherr, M.T. Avila, T.A. Blaxton, and G.K. Thaker Nicotine improves delayed recognition in schizophrenic patients Psychopharmacology (Berl) 174 2004 334 340
85. R. Naatanen, and S. Kahkonen Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review Int. J. Neuropsychopharmacol. 12 2009 125 135
86. J.M. Nelsen, and L. Goldstein Improvement of performance on an attention task with chronic nicotine treatment in rats Psychopharmacologia 26 1972 347 360
87. J.M. Nelsen, and L. Goldstein Chronic nicotine treatment in rats. 1. Acquisition and performance of an attention task Res. Commun. Chem. Pathol. Pharmacol. 5 1973 681 693
88. P.G. Nestor, S.F. Faux, R.W. McCarley, M.E. Shenton, and S.F. Sands Measurement of visual sustained attention in schizophrenia using signal detection analysis and a newly developed computerized CPT task Schizophr Res. 3 1990 329 332
89. P.A. Newhouse, A. Potter, and A. Singh Effects of nicotinic stimulation on cognitive performance Curr. Opin. Pharmacol. 4 2004 36 46
90. A. Olincy, J.G. Harris, L.L. Johnson, V. Pender, S. Kongs, D. Allensworth, J. Ellis, G.O. Zerbe, S. Leonard, K.E. Stevens, J.O. Stevens, L. Martin, L.E. Adler, F. Soti, W.R. Kem, and R. Freedman Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia Arch. Gen. Psychiatry 63 2006 630 638
91. R.L. Papke, C. Trocme-Thibierge, D. Guendisch, S. Abdullah, A.A. Rubaiy, and S.A. Bloom Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists J. Pharmacol. Exp. Ther. 337 2011 367 379
92. K.A. Perkins, J.E. Grobe, C. Fonte, J. Goettler, A.R. Caggiula, W.A. Reynolds, R.L. Stiller, A. Scierka, and R.G. Jacob Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans J. Pharmacol. Exp. Ther. 270 1994 628 638
93. J.M. Phillips, R.S. Ehrlichman, and S.J. Siegel Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma Neuroscience 144 2007 1314 1323
94. S. Phillips, and P. Fox An investigation into the effects of nicotine gum on short-term memory Psychopharmacology (Berl) 140 1998 429 433
95. R.M. Pigache Vigilance in schizophrenia and its disruption by impaired pre-attentive selection: a dysintegration hypothesis Cogn. Neuropsychiatry 4 1999 119 144
96. D. Quarta, C.G. Naylor, H.V. Morris, S. Patel, R.F. Genn, and I.P. Stolerman Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine Neuropharmacology 53 2007 421 430
97. R.J. Radek, K.L. Kohlhaas, L.E. Rueter, and E.G. Mohler Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists Curr. Pharm. Des. 16 2010 309 322
98. C. Saavedra-Velez, A. Yusim, D. Anbarasan, and J.P. Lindenmayer Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review J. Clin. Psychiatry 70 2009 104 112
99. K.A. Sacco, A. Termine, A. Seyal, M.M. Dudas, J.C. Vessicchio, S. Krishnan-Sarin, P.I. Jatlow, B.E. Wexler, and T.P. George Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms Arch. Gen. Psychiatry 62 2005 649 659
100. A.K. Sellin, M. Shad, and C. Tamminga Muscarinic agonists for the treatment of cognition in schizophrenia CNS Spectr. 13 2008 985 996
101. R.C. Smith, J. Warner-Cohen, M. Matute, E. Butler, E. Kelly, S. Vaidhyanathaswamy, and A. Khan Effects of nicotine nasal spray on cognitive function in schizophrenia Neuropsychopharmacology 31 2006 637 643
102. E. Stip, A.A. Sepehry, and S. Chouinard Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2 Clin. Neuropharmacol. 30 2007 218 229
103. I.P. Stolerman Inter-species consistency in the behavioural pharmacology of nicotine dependence Behav. Pharmacol. 10 1999 559 580
104. I.P. Stolerman, N.R. Mirza, and M. Shoaib Nicotine psychopharmacology: addiction, cognition and neuroadaptation Med. Res. Rev. 15 1995 47 72
105. K. Subramaniam, T.L. Luks, M. Fisher, G.V. Simpson, S. Nagarajan, and S. Vinogradov Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia Neuron 73 2012 842 853
106. B.L. Tan Profile of cognitive problems in schizophrenia and implications for vocational functioning Aust. Occup. Ther. J. 56 2009 220 228
107. R. Tandon, H.A. Nasrallah, and M.S. Keshavan Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future Schizophr Res. 122 2010 1 23
108. E. Temple, G.K. Deutsch, R.A. Poldrack, S.L. Miller, P. Tallal, M.M. Merzenich, and J.D. Gabrieli Neural deficits in children with dyslexia ameliorated by behavioral remediation: evidence from functional MRI Proc. Natl. Acad. Sci. U S A 100 2003 2860 2865
109. S.A. Tucci, R.F. Genn, and S.E. File Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of alpha 7 receptors Neuropharmacology 44 2003 367 373
110. E.W. Twamley, D.V. Jeste, and A.S. Bellack A review of cognitive training in schizophrenia Schizophr Bull. 29 2003 359 382
111. D.I. Velligan, R.S. Kern, and J.M. Gold Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies Schizophr Bull. 32 2006 474 485
112. A. Vercammen, E.H. de Haan, and A. Aleman Hearing a voice in the noise: auditory hallucinations and speech perception Psychol. Med. 38 2008 1177 1184
113. S. Vinogradov, M. Fisher, H. Warm, C. Holland, M.A. Kirshner, and B.G. Pollock The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia Am. J. Psychiatry 166 2009 1055 1062
114. Y. Wakasa, K. Takada, and T. Yanagita Reinforcing effect as a function of infusion speed in intravenous self-administration of nicotine in rhesus monkeys Nihon Shinkei Seishin Yakurigaku Zasshi 15 1995 53 59
115. H.K. White, and E.D. Levin Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease Psychopharmacology (Berl) 143 1999 158 165
116. S. Wonnacott, J. Barik, J. Dickinson, and I.W. Jones Nicotinic receptors modulate transmitter cross talk in the CNS J. Mol. Neurosci. 30 2006 137 140
117. K. Woollett, H.J. Spiers, and E.A. Maguire Talent in the taxi: a model system for exploring expertise Philosophical Trans. Royal Soc. B-Biological Sci. 364 2009 1407 1416
118. J.R. Wooltorton, V.I. Pidoplichko, R.S. Broide, and J.A. Dani Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas J. Neurosci. 23 2003 3176 3185
119. A.A. Woznica, K.A. Sacco, and T.P. George Prepulse inhibition deficits in schizophrenia are modified by smoking status Schizophr Res. 112 2009 86 90
120. M. Zink, S. Englisch, and A. Meyer-Lindenberg Polypharmacy in schizophrenia Curr. Opin. Psychiatry 23 2010 103 111